- Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
- Xeris to Participate in the Jefferies Global Healthcare Conference
- Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
- Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
- Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
More ▼
Key statistics
On Friday, Xeris Biopharma Holdings Inc (XERS:NSQ) closed at 2.26, 54.45% above the 52 week low of 1.46 set on Nov 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.24 |
---|---|
High | 2.41 |
Low | 2.19 |
Bid | 2.22 |
Offer | 2.26 |
Previous close | 2.22 |
Average volume | 1.51m |
---|---|
Shares outstanding | 148.26m |
Free float | 143.94m |
P/E (TTM) | -- |
Market cap | 334.32m USD |
EPS (TTM) | -0.4648 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼